
Sign up to save your podcasts
Or
In his weekly clinical update, Dr. Griffin discusses Merck’s RSV preventative monoclonal antibody Clesrovimab before reviewing the recent statistics on SARS-CoV-2 infection, if previous SARS-COV-2 infections predict the outcome of subsequent infections, if using COVID rapid diagnostic tests is cost effective, if the protein based vaccine NVX-CoV2327 elicits a durable immune response, if combination treatment of vaccine and antiviral drugs effectively protect against hospitalization, where to find PEMGARDA, what do when healthcare workers succumb to SARS-CoV-2 infection, and how COVID-19 may alter the cognitive trajectories of older patients.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, emailBecome a patron of TWiV!
Links for this episodeIntro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]
4.7
201201 ratings
In his weekly clinical update, Dr. Griffin discusses Merck’s RSV preventative monoclonal antibody Clesrovimab before reviewing the recent statistics on SARS-CoV-2 infection, if previous SARS-COV-2 infections predict the outcome of subsequent infections, if using COVID rapid diagnostic tests is cost effective, if the protein based vaccine NVX-CoV2327 elicits a durable immune response, if combination treatment of vaccine and antiviral drugs effectively protect against hospitalization, where to find PEMGARDA, what do when healthcare workers succumb to SARS-CoV-2 infection, and how COVID-19 may alter the cognitive trajectories of older patients.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, emailBecome a patron of TWiV!
Links for this episodeIntro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]
6,241 Listeners
593 Listeners
760 Listeners
3,911 Listeners
2,051 Listeners
452 Listeners
515 Listeners
171 Listeners
703 Listeners
268 Listeners
159 Listeners
620 Listeners
15,552 Listeners
85 Listeners
82 Listeners